 |
Previous Article | Next Article 
The Journal of Neuroscience, December 1, 1998, 18(23):9685-9694
Axotomy Reduces the Effect of Analgesic Opioids Yet Increases the
Effect of Nociceptin on Dorsal Root Ganglion Neurons
Fuad A.
Abdulla1 and
Peter A.
Smith2
1 Department of Physical Therapy, Tennessee State
University, Nashville, Tennessee 37290, and 2 Department of
Pharmacology and Division of Neuroscience, University of Alberta,
Edmonton, Alberta, Canada T6G 2H7
There is some doubt as to the effectiveness of opioids in the
management of neuropathic pain. We therefore examined the actions of
morphine and the opioid-like peptide nociceptin (both 1 µ) on dorsal
root ganglion (DRG) neurons that were isolated from control or from
nerve-injured rats. Both substances reduced -conotoxin (CTX)
GVIA-sensitive, N-type Ca2+ channel current
and small persistent nifedipine/ CTX-insensitive (non-N, non-L type)
current. Nifedipine-sensitive L-type current was unaffected. The effect
of nociceptin was antagonized by naloxone benzoylhydrazone (nalbzoh)
but not by naloxone. Sciatic nerve section (axotomy) profoundly
reduced the effects of morphine and the µ-receptor
agonist D-ala2,
N-Me-Phe4,Gly-ol5
enkephalin (DAMGO). The effect of the -agonist
[(+)-(5 ,7 ,8 )-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)-benzeneacetamide] (U69593) was unchanged, whereas the effect of nociceptin was
increased. All agonists produced their strongest effects
on the small, putative nociceptive cells and their weakest effects on
the largest cells. The -receptor agonist, enkephalin
D-pen2,5 (DPDPE), was without effect on
control or on axotomized cells. These and other data suggest that the
functional downregulation of µ-opioid receptors on sensory nerves
contributes to the poor efficacy of opioids in neuropathic pain. Also,
the increased effectiveness of nociceptin after axotomy supports the
hypothesis that its actions are mediated via a "non-opioid"
receptor. Pronounced suppression of Ca2+ channel
current in axotomized DRG neurons by nociceptin led to a reduction in
Ca2+-dependent K+ conductance and
a marked increase in excitability. Despite this, the spinal
administration of nociceptin or agonists that activate ORL1
(opioid-like orphan receptor) may prove to be of clinical interest in
the management of neuropathic pain.
Key words:
sympathetic pain; spinal analgesia; substantia
gelatinosa; superficial dorsal horn; C-fiber; causalgia; chronic
constriction injury
Copyright © 1998 Society for Neuroscience 0270-6474/98/18239685-10$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
H. N. Wenk, J.-D. Brederson, and C. N. Honda
Morphine Directly Inhibits Nociceptors in Inflamed Skin
J Neurophysiol,
April 1, 2006;
95(4):
2083 - 2097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Moran, W. F. Colmers, and P. A. Smith
Opioid-Like Actions of Neuropeptide Y in Rat Substantia Gelatinosa: Y1 Suppression of Inhibition and Y2 Suppression of Excitation
J Neurophysiol,
December 1, 2004;
92(6):
3266 - 3275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Valenzano, W. Miller, Z. Chen, S. Shan, G. Crumley, S. F. Victory, E. Davies, J.-C. Huang, N. Allie, S. J. Nolan, et al.
DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties
J. Pharmacol. Exp. Ther.,
August 1, 2004;
310(2):
783 - 792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. T. Whiteside, J. E. Harrison, M. S. Pearson, Z. Chen, Y. Rotshteyn, P. I. Turchin, J. D. Pomonis, L. Mark, K. Walker, and K. C. Brogle
DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat
J. Pharmacol. Exp. Ther.,
August 1, 2004;
310(2):
793 - 799.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Silbert, D. W. Beacham, and E. W. McCleskey
Quantitative Single-Cell Differences in {micro}-Opioid Receptor mRNA Distinguish Myelinated and Unmyelinated Nociceptors
J. Neurosci.,
January 1, 2003;
23(1):
34 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L Borgland, M. Connor, and M. J Christie
Nociceptin inhibits calcium channel currents in a subpopulation of small nociceptive trigeminal ganglion neurons in mouse
J. Physiol.,
October 1, 2001;
536(1):
35 - 47.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Mogil and G. W. Pasternak
The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family
Pharmacol. Rev.,
September 1, 2001;
53(3):
381 - 415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Inoue and H. Ueda
Protein Kinase C-Mediated Acute Tolerance to Peripheral {micro}-Opioid Analgesia in the Bradykinin-Nociception Test in Mice
J. Pharmacol. Exp. Ther.,
May 1, 2000;
293(2):
662 - 669.
[Abstract]
[Full Text]
|
 |
|
|

|